Results 11 to 20 of about 45,189 (317)

Patterns of Tumor Necrosis Factor Inhibitor (TNFi) Biosimilar Use Across United States Rheumatology Practices. [PDF]

, 2020
ObjectiveIt is unclear if biosimilars of biologics for inflammatory arthritis are realizing their promise to increase competition and improve accessibility.
Bansback, Nick, Curtis, Jeffrey R, Evans, Michael, He, Zeling, Huang, Jie, Johansson, Tracy, Liao, Katherine P, Michaud, Kaleb, Schmajuk, Gabriela   +8 more
core   +1 more source

Anti-rheumatic treatment and prosthetic joint infection: an observational study in 494 elective hip and knee arthroplasties

BMC Musculoskeletal Disorders, 2020
Background Surgical site infections are more frequent among patients with rheumatic disease. To what extent this is related to immunosuppressive antirheumatic drugs is unclear, as is the value of discontinuing medication perioperatively. The aim of study
Ylva Borgas, Anders Gülfe, Mikael Kindt, Anna Stefánsdóttir   +3 more
doaj   +1 more source

Updated American College of Rheumatology/American Association of Hip and Knee Surgeons guideline for the perioperative management of antirheumatic medication in patients with rheumatic diseases undergoing elective total hip or total knee arthroplasty 2022

Научно-практическая ревматология, 2023
The article presents updated guidelines developed by the American College of Rheumatology and the American Association of Hip and Knee Surgeons on the perioperative treatment of patients with rheumatoid arthritis, ankylosing spondylitis, psoriatic ...
V. N. Amirjanova, M. A. Makarov, A. E. Karateev, A. E. Khramov, S. V. Maglevaniy, A. V. Rozov, V. A. Nesterenko, E. L. Nasonov   +7 more
doaj   +1 more source

Efficacy and safety of ixekizumab through 52 weeks in two phase 3, randomised, controlled clinical trials in patients with active radiographic axial spondyloarthritis (COAST-V and COAST-W). [PDF]

, 2020
OBJECTIVES: To investigate the efficacy and safety of ixekizumab for up to 52 weeks in two phase 3 studies of patients with active radiographic axial spondyloarthritis (r-axSpA) who were biological disease-modifying antirheumatic drug (bDMARD)-naive ...
Baraliakos, X., Bertram, C.C., Bosch, F. van den, Carlier, H., COAST-V Study Grp, COAST-W Study Grp, Deodhar, A., Dougados, M., Ermann, J., Gallo, G., Gensler, L.S., Heijde, D. van der, Landewe, R., Li, X.Q., Maksymowych, W.P., Sieper, J., Tomita, T., Walsh, J.A., Wei, J.C.C., Zhao, F.Y.   +19 more
core   +3 more sources

Tuberculosis in patients using biological disease-modifying antirheumatic drugs

Northwestern Medical Journal, 2023
Aim: In rheumatic diseases, the possibility of developing tuberculosis (TB) increases due to both the disease itself and the biological disease-modifying antirheumatic drugs (bDMARDs) used for treatment.
Emine Afşin, Furkan Küçük, Murat Taşçı   +2 more
doaj   +1 more source

The in vitro effect of antirheumatic drugs on platelet function

Platelets, 2020
Several antirheumatic drugs lower the cardiovascular risk among rheumatoid arthritis patients. It is, however, unknown whether inhibition of platelet function contributes to this risk reduction.
Camilla Brødsgaard Nielsen, Christian Nielsen, Mads Nybo, Søren Andreas Just, Pernille Just Vinholt   +4 more
doaj   +1 more source

CARDIOVASCULAR DISEASES IN RHEUMATOID ARTHRITIS: LATEST DATA

Научно-практическая ревматология, 2016
The paper gives the latest data on the impact of traditional cardiovascular risk factors, chronic inflammation, antirheumatic therapy (disease-modifying antirheumatic drugs and biological agents) on the cardiovascular system.
T. V. Popkova, D. S. Novikova, E. L. Nasonov   +2 more
doaj   +1 more source

Effects of the anti-RANKL antibody denosumab on joint structural damage in patients with rheumatoid arthritis treated with conventional synthetic disease-modifying antirheumatic drugs (DESIRABLE study): a randomised, double-blind, placebo-controlled phase 3 trial. [PDF]

, 2019
ObjectiveTo evaluate the efficacy of denosumab in suppressing joint destruction when added to conventional synthetic disease-modifying antirheumatic drug (csDMARD) therapy in patients with rheumatoid arthritis (RA).MethodsThis was a multi-centre ...
Genant, Harry K, Nitta, Takaya, Okubo, Naoki, Soen, Satoshi, Takeuchi, Tsutomu, Tanaka, Sakae, Tanaka, Yoshiya, van der Heijde, Désirée, Yamanaka, Hisashi, Yoneda, Toshiyuki   +9 more
core   +2 more sources

Antirheumatic drugs and reproduction in women and men with chronic arthritis. [PDF]

, 2015
The impact of rheumatic disease on fertility and reproduction can be remarkable. Many disease-related factors can influence patients' sexual functioning, perturb fertility and limit family planning. Antirheumatic pharmacological treatment can also have a
Agosti, M, Andreoli, L, Bazzani, C, Nalli, C, Tincani, A   +4 more
core   +1 more source

Synergistic drug combinations from electronic health records and gene expression. [PDF]

, 2016
ObjectiveUsing electronic health records (EHRs) and biomolecular data, we sought to discover drug pairs with synergistic repurposing potential. EHRs provide real-world treatment and outcome patterns, while complementary biomolecular data, including ...
Chen, William, Daugherty, Aaron C, Desai, Manisha, Farrington, Carl, Gomez, Scarlett L, Hastie, Trevor, Kenkare, Pragati, Kurian, Allison W, Lim, Michael, Low, Yen S, Mathur, Maya, Radin, Andrew A, Schroeder, Elizabeth A, Seto, Tina, Shah, Nigam H, Sirota, Marina, Sledge, George W, Thompson, Caroline A, Weber, Susan, Yu, Peter P   +19 more
core   +2 more sources